RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF VISTIDE. CASES OF ACUTE RENAL FAILURE RESULTING IN DIALYSIS AND/OR CONTRIBUTING TO DEATH HAVE OCCURRED WITH AS FEW AS ONE OR TWO DOSES OF VISTIDE. TO REDUCE POSSIBLE NEPHROTOXICITY, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH VISTIDE INFUSION. RENAL FUNCTION (SERUM CREATININE AND URINE PROTEIN) MUST BE MONITORED WITHIN 48 HOURS PRIOR TO EACH DOSE OF VISTIDE AND THE DOSE OF VISTIDE MODIFIED FOR CHANGES IN RENAL FUNCTION AS APPROPRIATE (SEE DOSAGE AND ADMINISTRATION). VISTIDE IS CONTRAINDICATED IN PATIENTS WHO ARE RECEIVING OTHER NEPHROTOXIC AGENTS.
NEUTROPENIA HAS BEEN OBSERVED IN ASSOCIATION WITH VISTIDE TREATMENT. THEREFORE, NEUTROPHIL COUNTS SHOULD BE MONITORED DURING VISTIDE THERAPY.
VISTIDE IS INDICATED ONLY FOR THE TREATMENT OF CMV RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.
IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA (SEE CARCINOGENESIS, MUTAGENESIS, & IMPAIRMENT OF FERTILITY).
VISTIDE® is the brand name for cidofovir injection.
VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS.
Published Studies Related to Vistide (Cidofovir)
Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. [2009.10]
OBJECTIVE: Randomized controlled trial evaluating a topical treatment for cervical intraepithelial neoplasia 2 and 3 (CIN 2+) using cidofovir... CONCLUSION: The medical topical treatment with cidofovir, at this point, cannot replace conisation, but it is a promising candidate for topical chemotherapy of CIN 2+ lesions; a larger prospective randomized study is needed to confirm our results.
Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. [2008.07]
OBJECTIVES: We performed a prospective, double-blind, placebo-controlled, longitudinal adjuvant therapy trial to determine the efficacy of cidofovir in the treatment of severe recurrent respiratory papillomatosis (RRP). Although results of case series suggest that cidofovir may decrease the frequency and rapidity of papilloma regrowth, no blinded placebo-controlled studies have demonstrated efficacy... CONCLUSIONS: A randomized, blinded, placebo-controlled trial is necessary in the study of RRP, because the natural history of the disease can include remissions and reactivations. We found a significant improvement in the Derkay Severity Score 12 months after the baseline assessment in patients treated with cidofovir. This effect, however, was also seen in the placebo group. Accordingly, we were unable to provide proof of efficacy of cidofovir in the treatment of RRP.
Activity, safety, and feasibility of cidofovir and imiquimod for treatment of
vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised,
phase 2 trial. 
intraepithelial neoplasia... INTERPRETATION: Cidofovir and imiquimod were active, safe, and feasible for
Novel treatment of atypical human papillomavirus-associated epithelial hyperplasia with cidofovir. [2011.09]
CONCLUSIONS: Cidofovir formulated as a gel can be safe and effective for the treatment of epithelial hyperplasia in those with human immunodeficiency virus infection. Published by Elsevier Inc.
Intravenous cidofovir for resistant cutaneous warts in a patient with psoriasis treated with monoclonal antibodies. [2011.08]
Human papilloma virus is a common and often distressing cutaneous disease...
Clinical Trials Related to Vistide (Cidofovir)
Intravesical Cidofovir for Hemorrhagic Cystitis [Active, not recruiting]
The goal of this clinical research study is to learn how the drug cidofovir given as 1 dose
directly into the bladder is absorbed by the body. Researchers also want to measure the
amount of study drug in the body at different time points. The safety and tolerability of
this drug will also be studied.
Cidofovir is designed to fight certain viruses by blocking the virus cells from dividing.
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis [Recruiting]
The goal of this clinical research study is to learn if adding cidofovir to the standard of
care can improve symptoms of hemorrhagic cystitis caused by the BK virus as compared to
standard of care alone. The safety of cidofovir will also be studied.
Trial of Topical Cidofovir for the Prevention of Hair Growth [Completed]
This is a two-arm, single center placebo-controlled double-blind proof of concept study
which will evaluate the safety and efficacy of topical cidofovir (both 1% and 3%)compared to
placebo for the prevention of hair growth.
Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis [Withdrawn]
The goal of this clinical research study is to learn how the body absorbs and processes 1
dose of cidofovir that is given directly into the bladder, in patients with a viral
infection that is causing bleeding from the bladder.
The safety of this drug dose and the investigational way it is given (directly into the
bladder) will also be studied.
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration [Completed]
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against
herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro
studies. It is approved for the systemic treatment of human cytomegalovirus (HCMV) retinitis
in patients with AIDS and as a second line therapy for HCMV infections not responding to
ganciclovir or foscarnet.
In intensive care patients continuous venovenous haemofiltration (CVVH) is a
well-established extracorporal renal replacement therapy with a high clearance rate.
Pharmacokinetic studies of antifungal agents in critically ill patients treated with CVVH
are rare. Elimination of any given drug by renal replacement therapy is determined by
several major factors which are membrane specific, due to physico-chemical properties of the
drug and characteristics of the renal replacement technique used.
Study objective The trial is conducted to investigate the pharmacokinetics of cidofovir
during CVVH in critically ill patients. It is suspected that Hemofiltration will influence
cidofovir plasma levels.
Reports of Suspected Vistide (Cidofovir) Side Effects
Myelodysplastic Syndrome (4),
Therapeutic Response Decreased (4),
Drug Ineffective FOR Unapproved Indication (3),
Locked-in Syndrome (2),
Blindness Cortical (2),
Progressive Multifocal Leukoencephalopathy (2),
Cardiac Disorder (1),
Pericardial Effusion (1),
Ill-Defined Disorder (1), more >>
Page last updated: 2015-08-10